Immuron’s Travelan Sales Rise 16% in Q3 on Marketing and Retail Gains

Global Sales Growth Driven by Travelan

Immuron Limited (ASX:IMC; NASDAQ: IMRN) reported a 16% increase in unaudited Q3 FY26 sales to AUD 1.5 million, continuing the upward trajectory for its flagship immune supplement, Travelan®. Year-to-date sales reached AUD 5.7 million, a 7% improvement over the prior comparative period. This growth is anchored in Travelan’s expanding global presence, with Q3 sales outside Australia accounting for AUD 0.9 million, up 15% year-on-year.

Australia Sees Strong Quarter Despite Year-to-Date Dip

Australia’s Q3 sales more than doubled compared to the prior year, climbing over 100% to AUD 0.1 million and marking an 82% increase from the previous quarter. This surge was fuelled by heightened digital and social media marketing, increased promotions, and new store listings within key banner groups secured in FY25. However, year-to-date sales in Australia fell 65%, reflecting a softer start to the fiscal year. The company also reported initial sales to Jean Coutu, Quebec’s leading pharmacy chain, signalling growing traction in North America.

Canada Retail Expansion Supports Modest Sales Growth

Canada’s Q3 sales nudged up 1% to AUD 0.5 million, with year-to-date sales rising 10% to AUD 1.3 million. This growth follows a significant pipeline fill in Q1 FY25, placing Travelan in over a thousand retail doors across pharmacy and grocery groups. The ongoing pull-through from stores is supported by in-store educational programs, promotions, and social media campaigns, which helped drive an 82% quarter-on-quarter sales jump in Q3. The initial sales to Jean Coutu also highlight strategic progress in this market.

US Sales Growth Constrained by Currency and Market Dynamics

In the United States, Q3 sales increased by 1% year-on-year, supported by enhanced marketing initiatives including an improved Amazon store presence, localized Facebook and Instagram pages, and increased paid and organic social media. However, these efforts were partially offset by the Australian dollar’s appreciation against the US dollar, which weighed on reported revenue. The US remains a key focus for Immuron’s expansion, leveraging digital channels to build brand awareness.

Immuron’s recent FDA approval for its IMM-529 drug candidate and record sales growth underscore the company’s dual strategy of clinical development alongside commercial expansion. While Travelan drives current revenue, the pipeline’s progress could shape future growth trajectories.

Marketing and Distribution as Growth Engines

The company attributes Travelan’s sales momentum to a multi-pronged marketing approach: extensive digital and social media campaigns, promotional activities fostering new and repeat customers, and strategic retail partnerships. Notably, increased Southeast Asian travel has contributed to demand, aligning with Travelan’s positioning as a prophylactic against travelers’ diarrhea.

Despite these encouraging sales trends, the unaudited figures and currency fluctuations introduce some uncertainty. Immuron’s ability to sustain and scale this growth will likely depend on continued marketing investment, retail expansion, and navigating the competitive dietary supplement landscape.